filgotinib
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
- nasopharyngitis (10%)
- 4 uncomplicated herpes zoster cases
- 1 retinal vein occlusion
- no opportunistic infections, active tuberculosis, malignancies, GI perforations, or deaths.
Mechanism of action
- JAK1 inhibitor
More general terms
References
- ↑ Genovese MC, Kalunian K, Gottenberg JE et al Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease- Modifying Antirheumatic Drug TherapyThe FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334793 https://jamanetwork.com/journals/jama/fullarticle/2738551
Singh JA Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019;322(4):309-311 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334773 https://jamanetwork.com/journals/jama/fullarticle/2738528